137 related articles for article (PubMed ID: 15860667)
21. alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis.
Ha H; Lee JH; Kim HN; Kim HM; Kwak HB; Lee S; Kim HH; Lee ZH
J Immunol; 2006 Jan; 176(1):111-7. PubMed ID: 16365401
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture.
Okada Y; Lorenzo JA; Freeman AM; Tomita M; Morham SG; Raisz LG; Pilbeam CC
J Clin Invest; 2000 Mar; 105(6):823-32. PubMed ID: 10727451
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
24. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
25. Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration.
Kwak HB; Lee SW; Jin HM; Ha H; Lee SH; Takeshita S; Tanaka S; Kim HM; Kim HH; Lee ZH
Blood; 2005 Apr; 105(7):2963-9. PubMed ID: 15585657
[TBL] [Abstract][Full Text] [Related]
26. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
27. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
28. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
29. Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor.
Geng DC; Zhu XS; Mao HQ; Meng B; Chen L; Yang HL; Xu YZ
J Biomed Mater Res A; 2011 Dec; 99(4):516-22. PubMed ID: 21913318
[TBL] [Abstract][Full Text] [Related]
30. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation.
Lee NK; Choi YG; Baik JY; Han SY; Jeong DW; Bae YS; Kim N; Lee SY
Blood; 2005 Aug; 106(3):852-9. PubMed ID: 15817678
[TBL] [Abstract][Full Text] [Related]
31. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
Thummuri D; Naidu VGM; Chaudhari P
J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
[TBL] [Abstract][Full Text] [Related]
32. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
33. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
34. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
35. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
36. mu-Calpain regulates receptor activator of NF-kappaB ligand (RANKL)-supported osteoclastogenesis via NF-kappaB activation in RAW 264.7 cells.
Lee FY; Kim DW; Karmin JA; Hong D; Chang SS; Fujisawa M; Takayanagi H; Bigliani LU; Blaine TA; Lee HJ
J Biol Chem; 2005 Aug; 280(33):29929-36. PubMed ID: 15955824
[TBL] [Abstract][Full Text] [Related]
37. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
38. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.
Lam J; Takeshita S; Barker JE; Kanagawa O; Ross FP; Teitelbaum SL
J Clin Invest; 2000 Dec; 106(12):1481-8. PubMed ID: 11120755
[TBL] [Abstract][Full Text] [Related]
39. Dual modulation of osteoclast differentiation by lipopolysaccharide.
Zou W; Bar-Shavit Z
J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
